GlobeNewswire Inc.··Pomerantz LlpValneva Plunges 37% After Lyme Vaccine Fails Phase 3 Trial; Law Firm Launches Investigation
Valneva stock plummets 37% after Phase 3 Lyme vaccine candidate fails trial; law firm investigates potential securities fraud claims.
PFEVALNsecurities fraudstock price decline